ExoticRx · exoticrx.com/drugs/lotilaner
US brand names:Credelio
Lotilaner is dosed at 20–43 mg/kg PO q30 days in dogs, per CREDELIO - Lotilaner Tablet, Chewable [US Canine Product Label]. Elanco US Inc; 2017. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad403eb7-0c03-4bda-9698-3757860043cf — Verified against Plumb's Veterinary Drug Handbook, 10th Ed, p.811 (2026-08-01).. Verify against current literature before clinical use.
Isoxazoline ectoparasiticide blocking GABA and glutamate-gated chloride channels. Monthly flea and tick protection.
Seizure potential in dogs with history of neurologic disorders. Administer with food. Not for use in puppies <8 weeks or <1.4kg.
Species references:All Dog (Domestic) drugs
Each ExoticRx dose rule is graded by the strength of its primary evidence — see the editorial process.
A dog/cat sample is shown here. Cited dosing for all 1 species — reptiles, birds, pocket pets, livestock, and equine — is free on the per-species pages above. Pro adds the weight-based calculator for every species.
| Species | Route | Dose | Frequency | Evidence | Source |
|---|---|---|---|---|---|
| Dog (Domestic) | PO | 20–43 mg/kg | q30 days | Strong | CREDELIO - Lotilaner Tablet, Chewable [US Canine Product Label]. Elanco US Inc; 2017. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad403eb7-0c03-4bda-9698-3757860043cf — Verified against Plumb's Veterinary Drug Handbook, 10th Ed, p.811 (2026-08-01). |
| Dog (Domestic) | PO | 20–43 mg/kg | q30 days | Moderate | CREDELIO - Lotilaner Tablet, Chewable [US Canine Product Label]. Elanco US Inc; 2017. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad403eb7-0c03-4bda-9698-3757860043cf — Verified against Plumb's Veterinary Drug Handbook, 10th Ed, p.811 (2026-08-01). |
Upgrade to Pro or Student to unlock the full dose ranges and frequency for every species. The drug's mechanism, warnings, indications, and cited sources are free to read.
View PlansSource citations and evidence levels available on the live page. Reference only — verify against current literature before clinical use.